StockNews.com began coverage on shares of Galmed Pharmaceuticals (NASDAQ:GLMD – Free Report) in a research report released on Sunday morning. The firm issued a sell rating on the biopharmaceutical company’s stock. Galmed Pharmaceuticals Price Performance GLMD stock opened at $0.36 on Friday. Galmed Pharmaceuticals has a 12 month low of $0.26 and a 12 month […]